IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity
Clinical trial NCT02609386 · COMPLETED
Trial details
- NCT number
- NCT02609386
- Sponsor
- Brooklyn ImmunoTherapeutics, LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-01-11
- Primary completion
- 2022-02-28
- Enrollment
- 105
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.